Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Summit Therapeutics stock

SMMT
US86627T1088

Price

20.10
Today +/-
-1.63
Today %
-8.57 %
P

Summit Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Summit Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Summit Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Summit Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Summit Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Summit Therapeutics Stock Price History

DateSummit Therapeutics Price
10/1/202420.10 undefined
9/30/202421.90 undefined
9/27/202420.89 undefined
9/26/202422.81 undefined
9/25/202422.64 undefined
9/24/202424.00 undefined
9/23/202421.91 undefined
9/20/202424.39 undefined
9/19/202423.16 undefined
9/18/202424.56 undefined
9/17/202426.22 undefined
9/16/202429.48 undefined
9/13/202431.93 undefined
9/12/202427.41 undefined
9/11/202422.70 undefined
9/10/202422.97 undefined
9/9/202419.14 undefined
9/6/202412.27 undefined
9/5/202412.50 undefined
9/4/202412.00 undefined
9/3/202412.60 undefined

Summit Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Summit Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Summit Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Summit Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Summit Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Summit Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Summit Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Summit Therapeutics’s growth potential.

Summit Therapeutics Revenue, EBIT and net profit per share

DateSummit Therapeutics RevenueSummit Therapeutics EBITSummit Therapeutics Net Income
2029e1.1 B undefined0 undefined162.73 M undefined
2028e539.03 M undefined-166.4 M undefined-147.58 M undefined
2027e116.38 M undefined-388.96 M undefined-354.73 M undefined
2026e12.83 M undefined-281.71 M undefined-278.25 M undefined
2025e0 undefined-224 M undefined-212.35 M undefined
2024e0 undefined-184.71 M undefined-202.25 M undefined
20230 undefined-609.65 M undefined-614.93 M undefined
2022710,000 undefined-63.62 M undefined-78.78 M undefined
20211.81 M undefined-86.19 M undefined-88.6 M undefined
2020860,000 undefined-52.33 M undefined-52.7 M undefined
2019740,000 undefined-27.47 M undefined-29.13 M undefined
201857.09 M undefined11.29 M undefined9.9 M undefined
201716.1 M undefined-27.87 M undefined-26.35 M undefined
20162.3 M undefined-24.32 M undefined-21.37 M undefined
20150 undefined-20.85 M undefined-20.14 M undefined
20140 undefined-12.8 M undefined-11.36 M undefined
20130 undefined-6.69 M undefined-6.09 M undefined
20121.81 M undefined-3.58 M undefined-4.23 M undefined
20111.77 M undefined-3 M undefined-2.69 M undefined
2010760,000 undefined-3.73 M undefined-4.69 M undefined
2009190,000 undefined-6.97 M undefined-5.42 M undefined
2008190,000 undefined-10.72 M undefined-22.4 M undefined
20073.03 M undefined-11.77 M undefined-10.12 M undefined
20061.03 M undefined-4.38 M undefined-3.02 M undefined
2005530,000 undefined-1.8 M undefined-1.06 M undefined
2004110,000 undefined-290,000 undefined-50,000 undefined

Summit Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000000000.020.0600000000.010.120.541.1
---200.00---------700.00256.25--------866.67364.66103.34
---33.33---100.00100.00----75.0073.68-----------
0001000110000124200000000000
0-1-4-11-10-6-3-3-3-6-12-20-24-2711-27-52-86-63-609-184-223-281-388-1660
---400.00-366.67----300.00-300.00----1,200.00-168.7519.30---8,600.00-----2,341.67-334.48-30.80-
0-1-3-10-22-5-4-2-4-6-11-20-21-269-29-52-88-78-614-202-212-278-354-147162
--200.00233.33120.00-77.27-20.00-50.00100.0050.0083.3381.825.0023.81-134.62-422.2279.3169.23-11.36687.18-67.104.9531.1327.34-58.47-210.20
1.261.691.962.582.673.358.318.8915.8120.5139.659.161.5513.0917.2332.8369.5292.24193.34619.65000000
--------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Summit Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Summit Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20042005200620072008200920102011201220132014201520162017201820192020202120222023
                                       
14.1612.6318.2910.092.726.083.252.083.382.0311.2716.328.0628.535.263.866.471.8348.6186.24
000000000.0500003.96.10.50.31.50.30
000000000.5300006.68.35.19.915.75.80.85
030190340390000000000000000
0.050.320.41.031.420.170.20.120.220.352.421.210.6911.811.610.2118.43022.62
14.2112.9818.8811.464.536.253.452.24.182.3813.6917.5128.7550.861.279.687.697.4656.7189.71
01.262.624.273.710.340.260.150.020.040.060.080.122.921.51.33.55.16.06
00000000000000000000
0000000000000000000959
0.020.031.468.134.824.541.11.10.173.493.483.473.472113.913.111.510.400
0009.77000000.660.660.660.663.52.42221.81.89
000000000000000000.20.64.32
0.021.294.0822.178.534.881.361.250.194.194.24.214.2527.418.316.614.816.17.513.24
14.2314.2722.9633.6313.0611.134.813.454.376.5717.8921.723378.279.596.2102.4113.5664.2202.95
                                       
3.133.133.726.415.66.916.937.128.7910.080.410.610.620.10.30.70.812.17.02
0.010.010.020.020.030.030.030.030.030.040.020.050.050.140.190.240.290.380.51.07
-1.99-2.98-5.6-1.96-22.83-28.27-32.88-35.51-39.62-45.49-9.61-30.59-50.58-140.8-130.9-158.2-210.9-299.5-378.3-993.26
0000000000602050-4,300-4,800-4,800-3,800-2,200-1,900-2,448
00000000000000000000
14.0913.120.4527.28.568.273.682.412.864.7714.9616.08-3.49-4.455.878.979.583.3126.777.69
0.020.491.153.130.680.150.330.370.250.351.20.720.916.35.84.56.14.40.42.67
0.170.150.2100.810.950.80.881.071.472.512.392.986.45.76.24.712.41817.02
000.0200.250.010.080.040.20.050.070.17.0119.95.73.19.18.80.70.72
00000000000000000019.80
0707019014000000000036000000
0.190.711.453.321.881.111.211.291.521.873.783.2110.932.617.5613.819.925.638.920.41
000.61.221.180000005.035.924.40000494.5100
0001.881.020.940000.660.660.660.573.42.200000
00.691.181.281.321.180.210.210000.0723.742.34.43.63.24.54.24.85
00.691.784.383.522.120.210.2100.660.665.7630.1950.16.63.63.24.5498.7104.85
0.191.43.237.75.43.231.421.51.522.534.448.9741.0982.724.1617.423.130.1537.6125.26
14.2814.523.6834.913.9611.55.13.914.387.319.425.0537.678.379.9696.3102.6113.4664.3202.95
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Summit Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Summit Therapeutics's financial health and stability.

Assets

Summit Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Summit Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Summit Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Summit Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (k)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200420052006200720082009201020112012201320142015201620172018null20192020202120222023
0-1-3-11-13-5-5-3-4-6-12-23-25-2699-29-52-88-78-614
000112000000001111110
000000000000020000000
000101000002343-54-545008-2
00001-120102540159142739554
0000000000000000000010
00000000000-1-300000000
00-3-8-10-3-2-2-3-5-11-1712-21-35-35-20-48-72-41-76
0-1-1-1-10000000000000000
-13,0000-1,000001,0000000000-7,000000000-587,000
-13201010000000-6000000-587
000000000000000000000
0000000000000000000520-24
1409035015422260204646505078100111
140903501442022018444449507762086
-----------1.00-4.00--1.00-1.00-1.00-----
000000000000000000000
005-8-73-2-11-19511-6662825576-577
0.02-2.28-4.76-10.01-11.28-3.18-2.86-2.54-3.27-5.92-11.37-17.2512.05-22.32-35.270-21.1-48.53-72.9-42.2-76.89
000000000000000000000

Summit Therapeutics stock margins

The Summit Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Summit Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Summit Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Summit Therapeutics's sales revenue. A higher gross margin percentage indicates that the Summit Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Summit Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Summit Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Summit Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Summit Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Summit Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Summit Therapeutics Margin History

Summit Therapeutics Gross marginSummit Therapeutics Profit marginSummit Therapeutics EBIT marginSummit Therapeutics Profit margin
2029e75.3 %0 %14.83 %
2028e75.3 %-30.87 %-27.38 %
2027e75.3 %-334.21 %-304.81 %
2026e75.3 %-2,195.4 %-2,168.37 %
2025e75.3 %0 %0 %
2024e75.3 %0 %0 %
202375.3 %0 %0 %
202275.3 %-8,960.56 %-11,095.78 %
202175.3 %-4,761.88 %-4,895.03 %
202075.3 %-6,084.88 %-6,127.91 %
201975.3 %-3,712.16 %-3,936.49 %
201875.3 %19.78 %17.34 %
201776.34 %-173.11 %-163.66 %
201675.3 %-1,057.39 %-929.13 %
201575.3 %0 %0 %
201475.3 %0 %0 %
201375.3 %0 %0 %
2012100 %-197.79 %-233.7 %
2011100 %-169.49 %-151.98 %
2010100 %-490.79 %-617.11 %
2009100 %-3,668.42 %-2,852.63 %
200894.74 %-5,642.11 %-11,789.47 %
200758.42 %-388.45 %-333.99 %
200670.87 %-425.24 %-293.2 %
200556.6 %-339.62 %-200 %
200418.18 %-263.64 %-45.45 %

Summit Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Summit Therapeutics earnings per share therefore indicates how much revenue Summit Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Summit Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Summit Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Summit Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Summit Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Summit Therapeutics Revenue, EBIT and net profit per share

DateSummit Therapeutics Sales per ShareSummit Therapeutics EBIT per shareSummit Therapeutics Earnings per Share
2029e1.51 undefined0 undefined0.22 undefined
2028e0.74 undefined0 undefined-0.2 undefined
2027e0.16 undefined0 undefined-0.49 undefined
2026e0.02 undefined0 undefined-0.38 undefined
2025e0 undefined0 undefined-0.29 undefined
2024e0 undefined0 undefined-0.28 undefined
20230 undefined-0.98 undefined-0.99 undefined
20220 undefined-0.33 undefined-0.41 undefined
20210.02 undefined-0.93 undefined-0.96 undefined
20200.01 undefined-0.75 undefined-0.76 undefined
20190.02 undefined-0.84 undefined-0.89 undefined
20183.31 undefined0.66 undefined0.57 undefined
20171.23 undefined-2.13 undefined-2.01 undefined
20160.04 undefined-0.4 undefined-0.35 undefined
20150 undefined-0.35 undefined-0.34 undefined
20140 undefined-0.32 undefined-0.29 undefined
20130 undefined-0.33 undefined-0.3 undefined
20120.11 undefined-0.23 undefined-0.27 undefined
20110.2 undefined-0.34 undefined-0.3 undefined
20100.09 undefined-0.45 undefined-0.56 undefined
20090.06 undefined-2.08 undefined-1.62 undefined
20080.07 undefined-4.01 undefined-8.39 undefined
20071.17 undefined-4.56 undefined-3.92 undefined
20060.53 undefined-2.23 undefined-1.54 undefined
20050.31 undefined-1.07 undefined-0.63 undefined
20040.09 undefined-0.23 undefined-0.04 undefined

Summit Therapeutics business model

Summit Therapeutics Inc. is a global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines for the treatment of life-threatening and rare diseases. The company is headquartered in Massachusetts, USA and also has offices in Oxford, UK. Summit Therapeutics is one of the most popular companies on Eulerpool.com.

Summit Therapeutics Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Summit Therapeutics Revenue by Segment

Segmente202220212020
Licensing agreements705,000 USD1.81 M USD860,000 USD
Research collaboration agreement---

Summit Therapeutics Revenue by Region

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Summit Therapeutics Revenue by Segment

DateEuropeLatin AmericaUnited States
2022-705,000 USD-
2021-1.81 M USD-
2020-860,000 USD-

Summit Therapeutics SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Summit Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Summit Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Summit Therapeutics shares outstanding

The number of shares was Summit Therapeutics in 2023 — This indicates how many shares 619.646 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Summit Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Summit Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Summit Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Summit Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Summit Therapeutics.

Summit Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.06 -0.09  (-42.41 %)2024 Q2
3/31/2024-0.06 -0.06  (1.96 %)2024 Q1
12/31/20230 -0.04  (0 %)2023 Q4
9/30/20230 -0.03  (0 %)2023 Q3
6/30/20230 -0.02  (0 %)2023 Q2
3/31/20230 -0.06  (0 %)2023 Q1
12/31/20220 -0.07  (0 %)2022 Q4
9/30/2021-0.3 -1  (-238.07 %)2021 Q3
3/31/2021-0 -1.05  (-40,284.62 %)2021 Q1
12/31/2020-0 -0.9  (-40,809.09 %)2020 Q4
1
2

Eulerpool ESG Scorecard© for the Summit Therapeutics stock

Eulerpool World ESG Rating (EESG©)

53/ 100

🌱 Environment

54

👫 Social

82

🏛️ Governance

24

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees63
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Summit Therapeutics shareholders

%
Name
Stocks
Change
Date
75.68514 % Duggan (Robert William)548,369,10602/9/2024
4.87128 % Zanganeh (Mahkam)35,294,38826,0003/27/2024
4.35083 % Xia (Yu)31,523,53031,523,5302/9/2024
1.19241 % BlackRock Institutional Trust Company, N.A.8,639,514653,74012/31/2023
0.96428 % The Vanguard Group, Inc.6,986,588919,30712/31/2023
0.42588 % Geode Capital Management, L.L.C.3,085,666128,60312/31/2023
0.41077 % Soni (Manmeet Singh)2,976,19002/9/2024
0.33900 % State Street Global Advisors (US)2,456,168189,59912/31/2023
0.14093 % Northern Trust Investments, Inc.1,021,12354,78512/31/2023
0.13165 % Charles Schwab Investment Management, Inc.953,84613,05012/31/2023
1
2
3
4
5
...
10

Most common questions regarding Summit Therapeutics

What values and corporate philosophy does Summit Therapeutics represent?

Summit Therapeutics Inc represents values of innovation, dedication, and commitment to improving patient outcomes. With a strong corporate philosophy focused on advancing breakthrough treatments, Summit is renowned for its cutting-edge research and development initiatives in the pharmaceutical industry. The company strives to leverage its expertise and strategic partnerships to deliver high-quality therapies and address unmet medical needs. Summit Therapeutics Inc's commitment to scientific excellence and patient-centric approach makes it an industry leader, dedicated to transforming healthcare and making a positive impact on people's lives.

In which countries and regions is Summit Therapeutics primarily present?

Summit Therapeutics Inc is primarily present in the United States and the United Kingdom. They have established their headquarters in Cambridge, Massachusetts, USA, and have an additional office in Oxfordshire, England. The company specializes in the discovery and development of novel medicines to treat rare diseases and infectious diseases. With a focus on innovative research and collaboration, Summit Therapeutics Inc aims to deliver transformative therapies that address significant unmet medical needs.

What significant milestones has the company Summit Therapeutics achieved?

Summit Therapeutics Inc has achieved several significant milestones. The company successfully completed Phase II clinical trials for its lead antibiotic candidate, Ridinilazole, demonstrating its effectiveness in treating Clostridium difficile infection. Summit Therapeutics also received Fast Track designation from the U.S. FDA for Ridinilazole, speeding up the review process. In addition, the company secured a collaboration with the Bill & Melinda Gates Foundation to develop new antibiotics targeting gonorrhea, emphasizing their commitment to addressing antimicrobial resistance. Moreover, Summit Therapeutics listed on NASDAQ exchange, enhancing its visibility and accessibility to investors. These milestones highlight the company's progress and dedication to advancing innovative therapies to address unmet medical needs.

What is the history and background of the company Summit Therapeutics?

Summit Therapeutics Inc is a renowned biotechnology company specializing in developing innovative medicines for patients with rare diseases. Founded in 2003, Summit Therapeutics has made significant strides in the field of precision medicine. With a strong focus on genetic diseases, the company uses its proprietary technologies to discover and advance promising therapeutics options. Summit Therapeutics Inc has a track record of successful collaborations with renowned academic institutions and pharmaceutical companies, diversifying its pipeline and expanding its research capabilities. By combining cutting-edge science and strategic partnerships, Summit Therapeutics strives to improve the lives of patients worldwide with groundbreaking treatments and therapies.

Who are the main competitors of Summit Therapeutics in the market?

The main competitors of Summit Therapeutics Inc in the market include pharmaceutical companies such as AstraZeneca, Pfizer, Novartis, and GlaxoSmithKline.

In which industries is Summit Therapeutics primarily active?

Summit Therapeutics Inc is primarily active in the pharmaceutical industry. With a focus on developing innovative therapies, Summit Therapeutics engages in drug discovery and development for various medical conditions. The company's expertise lies in the research and development of novel antibiotics, specifically targeting the treatment of bacterial infections. Summit Therapeutics works closely with healthcare professionals and regulatory agencies to bring safe and effective therapeutic solutions to patients in need. As a leading player in the pharmaceutical industry, Summit Therapeutics Inc continuously strives to enhance healthcare outcomes and improve the quality of life for individuals worldwide.

What is the business model of Summit Therapeutics?

Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of novel medicines to treat rare and infectious diseases. Their business model revolves around leveraging their expertise in genetic research and drug development to advance innovative therapies. By utilizing their proprietary Discuva Platform, Summit Therapeutics aims to identify potential protein targets for drug discovery and design personalized medicines. With a strong emphasis on precision medicine, their goal is to improve patient outcomes by delivering targeted therapeutics tailored to individual needs. Summit Therapeutics Inc. is dedicated to research and collaboration to address unmet medical needs and enhance global healthcare.

What is the P/E ratio of Summit Therapeutics 2024?

The Summit Therapeutics P/E ratio is -61.58.

What is the P/S ratio of Summit Therapeutics 2024?

The Summit Therapeutics P/S ratio is 0.

What is the AlleAktien quality score of Summit Therapeutics?

The AlleAktien quality score for Summit Therapeutics is 3/10.

What is the revenue of Summit Therapeutics 2024?

The revenue cannot currently be calculated for Summit Therapeutics.

How high is the profit of Summit Therapeutics 2024?

The expected Summit Therapeutics profit is -202.25 M USD.

What is the business model of Summit Therapeutics

Summit Therapeutics Inc. is a biopharmaceutical company specializing in the discovery and development of innovative therapeutic options for rare diseases. The company is headquartered in Oxford, United Kingdom, and also operates locations in the United States. The business model of Summit Therapeutics primarily focuses on identifying and developing medical treatment options for genetically inherited diseases. The company combines comprehensive research and development, strategic partnerships, and careful market research to offer a wide range of products and services. Summit Therapeutics' research area is dedicated to identifying biomarkers and disease mechanisms that play a role in rare diseases. The company utilizes cutting-edge technology and analytical approaches to advance groundbreaking developments in this field. Summit Therapeutics also collaborates closely with external partners to exchange resources and expertise and create synergies. The company has strategic partnerships with leading institutions such as the Children's Hospital of Philadelphia and the University of Oxford, as well as biotech and pharmaceutical companies like Japanese company Sarepta and Swiss company Lonza. Summit Therapeutics' products include a range of drugs in the clinical development stage for the treatment of neuromuscular disorders such as Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). The company also has an active research branch focused on developing drugs to combat diseases such as C. difficile infections and cystic fibrosis. In addition to these core activities, Summit Therapeutics also offers a wide range of services including consulting, drug discovery platforms, partnering, and clinical development. These services are tailored to the needs of pharmaceutical companies and academic institutions, aiming to accelerate their research and development activities. Overall, Summit Therapeutics has a differentiated business model focused on identifying and developing therapeutic options for rare diseases. The company strives to be a leader in this field by leveraging its innovative research and strategic partnerships to offer a wide range of products and services.

What is the Summit Therapeutics dividend?

Summit Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Summit Therapeutics pay dividends?

The dividend cannot currently be calculated for Summit Therapeutics or the company does not pay out a dividend.

What is the Summit Therapeutics ISIN?

The ISIN of Summit Therapeutics is US86627T1088.

What is the Summit Therapeutics ticker?

The ticker of Summit Therapeutics is SMMT.

How much dividend does Summit Therapeutics pay?

Over the past 12 months, Summit Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Summit Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Summit Therapeutics?

The current dividend yield of Summit Therapeutics is .

When does Summit Therapeutics pay dividends?

Summit Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Summit Therapeutics?

Summit Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Summit Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Summit Therapeutics located?

Summit Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Summit Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Summit Therapeutics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Summit Therapeutics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Summit Therapeutics in the year 2023?

In the year 2023, Summit Therapeutics distributed 0 USD as dividends.

In which currency does Summit Therapeutics pay out the dividend?

The dividends of Summit Therapeutics are distributed in USD.

All fundamentals about Summit Therapeutics

Our stock analysis for Summit Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Summit Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.